Public trial registry of the CCC-Munich

Trial TIGER

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
TIGER
World
Full title
:

Behandlungsoptimierung von neu diagnostiziertem positivem Ph/BCR-ABL

World
Description
:

Treatment optimization of newly diagnosed Ph/BCR-ABL positive
patients with chronic myeloid leukemia (CML) in chronic phase
with nilotinib vs. nilotinib plus interferon alpha induction and
nilotinib or interferon alpha maintenance therapy

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
Medizinische Klinik III, Telefon: 089440072551
Indications
Classification Code Description
ICD-10-GM C92.1- Chronische myeloische Leukämie [CML], BCR/ABL-positiv
- Bloodcancer (leukemia, lymphoma)
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2022-12-31 / Unknown
Participants
Function Prename Surname Organization
World Principal Investigator Karsten Spiekermann Keine Organisationseinheit angegeben Magnifier